Researchers at Eureka Therapeutics and Memorial Sloan-Kettering have targeted Wilms tumor 1-positive cancer cells with a mAb against peptide fragments derived from the protein that are presented on the cells' surface. The biotech hopes to have the mAb in a Phase I trial in leukemia within two years.